Malcolm Boyce is the founder and Chief Executive of Trio Medicines Ltd, which is a subsidiary of Hammersmith Medicines Research (a contract research organisation offering full services for phase 1 and early phase 2 clinical trials) of which Malcolm is founder and medical director.
He qualified in physiology and medicine in Bristol, and subsequently became: Fellow of the Royal College of Physicians; Fellow of the Faculty of Pharmaceutical Medicine; and Fellow of the British Pharmacological Society. He is an Honorary Senior Lecturer in Clinical Pharmacology at St Bartholomew’s Hospital Medical College.
He has held various posts in clinical and academic medicine, and has worked for several of the major pharmaceutical companies. During his time in the industry, he carried out or co-ordinated numerous clinical trials in Europe and the USA across all phases of drug development, with a wide variety of new compounds.
He is a member or chairman of the: Faculty of Pharmaceutical Medicine DHP/CHP Advisory Committee; Association of Human Pharmacologists in the Pharmaceutical Industry; MHRA GCP Consultative Committee; NRES Phase 1 Advisory Group; and London Research Ethics Committee. He has published over 145 papers in journals and books on drug development and research ethics.